Welcome to our dedicated page for Avidity Biosciences SEC filings (Ticker: RNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Avidity Biosciences’ journey from lab bench to potential FDA approval means wading through dense disclosures on its Antibody Oligonucleotide Conjugate platform, clinical trial costs, and collaboration milestones. Those details hide in 200-page 10-Ks and rapid-fire 8-Ks—documents few investors have time to dissect.
Stock Titan eliminates that bottleneck. Our AI turns every Avidity Biosciences quarterly earnings report 10-Q filing, annual report 10-K simplified, and Avidity Biosciences 8-K material events explained into plain-English highlights within minutes of hitting EDGAR. Need to monitor Avidity Biosciences insider trading Form 4 transactions? We stream Form 4 insider transactions real-time, flag executive stock sales, and cross-reference them with upcoming data releases.
- AI-powered summaries clarify R&D spend, cash runway, and AOC pipeline milestones.
- Real-time alerts for Avidity Biosciences executive stock transactions Form 4.
- Side-by-side trend charts for revenue from collaborations and quarterly burn.
- Keyword search—find “del-desiran Phase 2 costs” inside hundreds of pages instantly.
Whether you’re comparing dilution risk before the next capital raise or studying compensation in the Avidity Biosciences proxy statement executive compensation, our platform answers the questions investors actually ask: “How healthy is the balance sheet?”, “Which trials are fully funded?”, “What did the CEO buy last quarter?”. Stop scrolling; start understanding Avidity Biosciences SEC documents with AI.
Avidity Biosciences, Inc. is asking stockholders to approve its acquisition by Novartis AG, under which each share of Company Common Stock will be converted into the right to receive $72.00 in cash, subject to tax withholding. Before the merger, Avidity will separate its early-stage precision cardiology programs into a new company, Bryce Therapeutics, Inc. (SpinCo), and either distribute SpinCo stock at a ratio of one SpinCo share for every ten Avidity shares or sell SpinCo to a third party and distribute the cash proceeds pro rata. In the distribution scenario, SpinCo is expected to receive $270 million of funding (subject to adjustments) and operate as an independent public company. Avidity’s board unanimously determined the merger, spin-off and related agreements are fair and in stockholders’ best interests and recommends voting in favor of all proposals.
Avidity Biosciences (RNA) reported Q3 2025 results with collaboration revenue of $12,475k and operating expenses of $201,281k, leading to a net loss of $174,442k ($1.27 per share). Cash, cash equivalents and marketable securities totaled $1,875,836k as of September 30, 2025, supported by recent equity raises.
The company strengthened its balance sheet with an underwritten public offering of 17,250,000 shares for approximately $651.4 million in net proceeds and sold 5,646,583 shares via its ATM for $185.5 million. As of October 31, 2025, shares outstanding were 150,675,742.
Subsequent event: Avidity entered a definitive agreement to be acquired by Novartis for $72.00 per share in cash, alongside a planned spin-off of precision cardiology assets at a distribution ratio of 1 SpinCo share per 10 Avidity shares, funded with $270 million, subject to customary conditions. R&D programs advanced, including del-zota in DMD44 (Breakthrough Therapy) and ongoing pivotal studies in DM1 and FSHD. Commitments include a $621.6 million manufacturing agreement for 2026–2028 and new headquarters leases.
Avidity Biosciences (RNA) furnished quarterly results information via Form 8-K. The company reported that it issued a press release announcing financial results for the quarter ended September 30, 2025, and attached the release as Exhibit 99.1. The Item 2.02 information, including Exhibit 99.1, is provided under General Instruction B.2 and is not deemed filed for liability purposes under the Exchange Act.
Novartis filed definitive additional proxy materials regarding its proposed acquisition of Avidity Biosciences (RNA), outlining strategic rationale and next steps. CEO Vasant Narasimhan highlighted Avidity’s antibody-oligonucleotide conjugate platform, which pairs monoclonal antibodies with siRNA or antisense oligonucleotides to target tissues beyond the liver, with a focus on muscle for neuromuscular diseases.
The materials describe plans tied to Avidity’s programs in myotonic dystrophy (DM1), facioscapulohumeral muscular dystrophy (FSHD) and Duchenne muscular dystrophy (DMD). Novartis stated it raised guidance to 6% sales growth over the next five years and expects a core margin of 40%+ in 2029, and noted more investment given the potential acquisition. Avidity will file a preliminary and definitive proxy for a special meeting related to the Transactions, which also contemplate a spin-off or sale of SpinCo and a merger. The filing includes customary cautionary and solicitation disclosures.
Novartis AG filed a DFAN14A featuring an employee letter about its proposed acquisition of Avidity Biosciences (RNA) and a related spin-off or sale of SpinCo. The message highlights Avidity’s RNA therapeutics platform and late-stage programs in DM1, FSHD, and DMD, and notes that both companies will operate separately until closing.
Avidity will deliver a definitive proxy statement and proxy card to stockholders in advance of a special meeting to consider the transactions. The communication includes extensive forward‑looking statements and emphasizes conditions such as regulatory approvals and Avidity stockholder approval. It also outlines potential risks, including disruption from the transactions, execution of the SpinCo separation, competing proposals, and possible stockholder litigation.
Novartis AG filed definitive additional proxy materials (DFAN14A) under Rule 14a-12 regarding its proposed acquisition of Avidity Biosciences (RNA), which also contemplates a spin-off or sale of a subsidiary referred to as SpinCo. The materials include social media posts and an internal email dated October 27, 2025.
Avidity intends to file a preliminary and definitive proxy statement, and its stockholders will receive a definitive proxy statement and proxy card in advance of a special meeting to vote on the Transactions. Completion remains subject to customary closing conditions, including regulatory approvals and approval of Avidity’s stockholders. The communication emphasizes that it is not an offer to sell or solicit any security and includes forward-looking statements with outlined risks.
Avidity Biosciences (RNA) agreed to be acquired by Novartis for $72.00 per share in cash, with Avidity becoming an indirect wholly owned subsidiary after closing. The deal is conditioned on a pre-closing separation of early-stage precision cardiology assets into Bryce Therapeutics (SpinCo) and completion of either a pro rata Spin-Off or a permitted sale of SpinCo.
Spin-Off terms: stockholders are to receive 1 share of SpinCo Common Stock for every 10 Avidity shares; SpinCo is to be funded with $270 million (net of SpinCo’s existing cash, cash equivalents and marketable securities) and is intended to list on Nasdaq. Equity awards are to be cashed out at $72 per underlying share at closing, with holders as of the Spin-Off record date also entitled to the 1-for-10 SpinCo distribution. Warrants will receive the merger consideration and may receive cash from any permitted sale proceeds pursuant to their terms.
Conditions and timing: closing requires effectiveness of the Spin-Off registration, completion of the Spin-Off or permitted sale, HSR clearance, other specified antitrust clearances, absence of legal restraints, no Company Material Adverse Effect, and majority stockholder approval. The parties expect closing in the first half of 2026. The Outside Date is July 27, 2026, extendable to October 26, 2026 in specified circumstances. The agreement includes a $450 million termination fee and a $600 million reverse termination fee. The Merger and Spin-Off are expected to be taxable to stockholders.
Novartis AG filed additional proxy solicitation materials related to its planned acquisition of Avidity Biosciences (RNA), alongside a proposed spin-off or sale of SpinCo. The materials note that Avidity will file a preliminary and definitive proxy statement, and that completion remains subject to customary conditions, including regulatory clearances and approval of Avidity’s stockholders.
The content includes a media report that Novartis agreed to buy Avidity for $12bn, or $72 per share, a 46% premium to the prior close, with an enterprise value of $11bn. The report also states Avidity will spin off its cardiovascular programs and that Novartis expects the deal to lift its 2024–2029 CAGR from 5% to 6% while diluting profitability by 1–2 percentage points, without changing this year’s guidance. Disclosures emphasize forward-looking risks and instruct Avidity stockholders to read the definitive proxy statement when available.
Avidity Biosciences (RNA) reported insider activity by its Chief Medical Officer. On October 22, 2025, the officer exercised a stock option for 2,209 shares at $10.16 and sold 2,209 shares at a weighted-average price of $47.5394, executed under a Rule 10b5-1 trading plan adopted on June 12, 2024.
Following these transactions, the officer held 38,867 shares of common stock directly and 68,458 derivative securities (stock options). The referenced option was granted on January 20, 2024 and vests in equal monthly installments of 2,208 shares until fully vested and exercisable on January 20, 2028.
FAQ
What is the current stock price of Avidity Biosciences (RNA)?
What is the market cap of Avidity Biosciences (RNA)?
